Top Regional Bank Stocks For 2015

Top Regional Bank Stocks For 2015: Immunomedics Inc.(IMMU)

Immunomedics, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and marketing of monoclonal, antibody-based products for the treatment of cancer, autoimmune, and other serious diseases in the United States and Europe. The company?s products include epratuzumab, a Phase III clinical trail product for the treatment of systemic lupus erythematosus and non-Hodgkin?s lymphoma; Veltuzumab, a Phase I/II clinical study completed product for the treatment of patients with non-Hodgkin?s lymphoma, immune thrombocytopenic purpura, and chronic lymphocytic leukemia; Yttrium Y 90 Clivatuzumab tetraxetan, a humanized monoclonal antibody for pancreatic cancer that is in Phase Ib/II clinical trail; and Yttrium Y 90 epratuzumab tetraxetan, a Phase I/II clinical study product for patients with non-Hodgkin?s lymphoma. Its early phase clinical trial products comprise Milatuzumab, a transmembrane protein product for antibody-drug conjugate therapy. The com pan y also develops Dock-and-Lock methodology for making fusion proteins and multifunctional antibodies, as well as a new method of delivering imaging and therapeutic agents selectively to disease, primarily different solid cancers. In addition, it markets and sells a diagnostic product, LeukoScan, which is used to treat infection and inflammation in bones for patients with suspected osteomyelitis, including patients with diabetic foot ulcers. Immunomedics, Inc. has a license and collaboration agreement with Nycomed GmbH to develop, manufacture, and commercialize veltuzumab in the subcutaneous formulation for the treatment of various non-cancer indications; and a partnership and cross-licensing agreement with Alexis Biotech Ltd., to develop vaccines against cancers that include melanoma and chronic lymphocytic leukemia, and infectious diseases, such as AIDS. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey.

Advisors' Opinion! :

• [By Roberto Pedone]

  Another under-$10 stock that's starting to move within range of triggering a big breakout trade is Immunomedics (IMMU), which is focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. This stock is off to a very bullish start in 2013, with shares up sharply by 110%.

  If you take a look at the chart for Immunomedics, you'll notice that this stock has been uptrending decent for the last month, with shares moving higher from its low of $4.85 to its recent high of $6.54 a share. During that uptrend, shares of IMMU have been consistently making higher lows and higher highs, which is bullish technical price action. This uptrend is coming after shares of IMMU downtrended during July from $6.91 to that $4.65 a share low. Shares of IMMU are now starting to push within range of triggering a big breakout trade.

  Market players should now look for long-biased trades in IMMU if it manages to break out above some near-term overhead resistance at $6.54 a share and then once it clears its 52-week high at $6.91 a share with high volume. Look for a sustained move or close above those levels with volume that registers near or above its three-month average volume of 1.15 million shares. If that breakout triggers soon, then IMMU will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that breakout are $8 to $10 a share, or possibly even north of $10 a share.

  Traders can look to buy IMMU off any weakness to anticipate that breakout and simply use a stop that sits right below its 50-day at $5.52 a share or below more support at $5 a share. One can also buy IMMU off strength once it clears those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

• [By Sean Williams]

  In terms of clinical data, small-cap biotechnology company! Immunome! dics (NASDAQ: IMMU  ) jumped by double digits after reporting early stage, but nonetheless positive, data from its antibody-drug conjugate program. Two of Immunomedics' ADC's, IMMU-130 which is targeted at metastatic colorectal cancer, and IMMU-132, which is being tested on 13 different cancer types, demonstrated tumor shrinkage and some partial responses. We're still a long way from an approval, but ADC's certainly look like one pathway to effectively treating cancer. Make sure this is a company you've added to your Watchlist.

• [By Sean Williams]

  What: Shares of Immunomedics (NASDAQ: IMMU  ) , a biopharmaceutical company researching monoclonal, antibody-based products to treat cancer and other autoimmune disorders, jumped as much as 15% after providing a clinical update on its antibody-drug conjugate programs.

• [By George Budwell]

  Immunomedics (NASDAQ: IMMU  ) develops monoclonal antibodies for the treatment of cancer, autoimmune disorders, and other life-threatening diseases. The company has six products in clinical trials for a variety of diseases. Shares of Immunomedics have fallen hard and fast since the company announced the termination of a licensing deal with Takeda Pharmaceutical over veltuzumab last month. Even positive clinical trial results for 90-Y clivatuzumab, a treatment for advanced pancreatic cancer, failed to slow the fall. And last week, the pace of the decline picked up to the tune of a 15% drop on heavy volume.

source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/top-regional-bank-stocks-for-2015.html